News

SK Hynix has suspended its plans to take subsidiary Solidigm public via IPO, which reduces near-term cash requirements and allows the South Korean chipmaker to trim financial losses. This signals a pullback on capital-raising plans amid challenging semiconductor market conditions, but also suggests management confidence in internal cash generation. For Australian investors, this matters because semiconductor supply chain stability and pricing affect both local tech stocks and exporters—watch for updates on Solidigm's operational strategy and whether other chip firms adjust capex or IPO timelines similarly.

Rio Tinto is investing $1.9B to develop the Kangwinan bauxite project in Queensland, reinforcing its position as a major alumina producer and signalling confidence in long-term demand. This capital commitment supports local jobs and production capacity at Weipa, Australia's largest bauxite operation, and reflects the company's strategy to maintain supply amid global competition. For ASX investors, this is positive for RIO's earnings trajectory and the broader materials sector, though the project's returns will depend on bauxite and alumina prices staying resilient—watch commodity cycles and Chinese aluminium demand.

L'Oréal's CEO has flagged that the rising adoption of GLP-1 weight loss drugs (like Ozempic) is materially impacting demand for beauty and skincare products. This is significant because beauty companies rely on consumers spending discretionary income on cosmetics and skincare—drugs that suppress appetite and reduce interest in appearance-focused consumption directly threaten that revenue. For Australian investors, this highlights a structural headwind affecting the global beauty and luxury sectors; the phenomenon is already evident in some earnings reports, and we should expect more beauty companies to flag this in coming guidance.

Newmont, the world's largest gold miner, has beaten quarterly profit expectations driven by higher gold prices and recovery at its Cadia mine in NSW—a major asset for Australian investors. This is positive for gold-exposed stocks and signals improving operational performance in the sector, though results are partly lifted by external gold price strength rather than pure operational gains. Australian materials stocks like Rio Tinto and BHP typically track commodity prices and mining sentiment, so this earnings beat could support broader sector momentum in coming weeks.

Western Digital reported a strong 161% jump in non-GAAP EPS for Q1, with forward guidance suggesting continued momentum into Q2—a positive signal for the storage and semiconductor sector after recent weakness. This recovery reflects improving demand for data storage, particularly in cloud and AI-related infrastructure, which has been a key driver for tech hardware companies globally. Australian tech investors should monitor whether this strength spreads to other semiconductor and hardware plays on the ASX, though WDC's US listing means direct exposure is limited to international portfolios.

Meta is creating a dual-class share structure to fund massive AI infrastructure spending while preserving Mark Zuckerberg's voting control at 60.6%. The move allows the company to issue equity (via a 1:1 non-voting share distribution in January) to raise capital for its 'Year of Efficiency' capex plans without diluting founder voting power—a controversial but legally permissible tactic. For Australian investors holding $META, this increases share count but doesn't immediately change economic ownership; however, it signals Meta's confidence in AI ROI and telegraphs sustained heavy spending ahead, which markets will scrutinise in earnings calls.

Moderna's stock fell on reports that Phase 3 data for its jointly-developed cancer vaccine with Merck may have leaked ahead of an official weekend presentation at a medical conference. This matters because the market doesn't yet know whether the data is positive or negative, creating uncertainty—and leaks typically suggest disappointing results that companies want to control carefully. Australian investors should watch the official data release for clarity on efficacy and safety outcomes, as cancer vaccine breakthroughs could reshape the biotech and pharma landscape, while a miss could pressure both Moderna and Merck share prices.

Tesla's net profit fell 43% year-on-year to $787 million as the company aggressively invests in robotics (Optimus) and autonomous driving technology, prioritising long-term growth over near-term earnings. While the pivot signals Musk's confidence in these high-margin future revenue streams, the sharp earnings miss reflects near-term margin pressure and elevated capex, which typically weighs on growth stocks when profitability deteriorates. For Australian investors holding tech-heavy portfolios or US-exposed ETFs, this underscores broader volatility in mega-cap tech as AI bets compete with quarterly performance—watch whether Tesla can deliver meaningful Cybercab revenue by year-end to justify current valuations.

Palantir is reportedly continuing to secure government and commercial contracts heading into Q3 earnings, according to Citi analysis. This suggests the company's diversification beyond pure government work is progressing, which could support revenue growth and margin expansion. For Australian investors, Palantir exposure is limited on the ASX, but the stock is widely held in US-focused ETFs and tech funds; the earnings beat potential could provide near-term upside for those positions, though the core narrative remains execution on AI commercialisation.

Micron and other semiconductor stocks are selling off after two negative signals: Tesla cut its near-term capex guidance, reducing expected chip demand, and Lam Research (a key chip equipment supplier) issued a weaker-than-expected forecast. This matters because chip demand is highly cyclical and tied to tech spending—when major customers like Tesla pull back, it signals softer demand ahead. Australian investors exposed to semiconductor plays through ETFs or direct holdings should monitor whether this reflects a temporary pause or broader weakness in the AI/capex cycle.

Barclays is cutting 5,000 jobs (5% of workforce) as part of cost-reduction initiatives enabled by AI productivity gains, announced alongside improved quarterly profits. This reflects a broader industry trend of banks using automation to reduce headcount and boost margins—a structural shift that will likely pressure banking sector employment but supports profitability near-term. Australian investors should monitor how local banks (CBA, NAB, Westpac, ANZ) respond to similar AI-driven efficiency pressures and whether ASX200 financial stocks benefit from or face headwinds from this automation wave.

Wyndham Hotels & Resorts has raised its earnings guidance after beating EBITDA expectations, signalling stronger operational performance than previously anticipated. However, analyst Jefferies' cautious stance on upside suggests the market may have already priced in much of this positive momentum, limiting further share price appreciation from current levels. For Australian investors with exposure to hospitality or travel-exposed portfolios, this reflects broader strength in the leisure sector, though currency headwinds on USD earnings remain a consideration.

Meta and Tesla earnings results have triggered a sell-off in Canadian equity futures, suggesting investor caution ahead of the open. Both mega-cap tech stocks drive significant index weight globally, so weaker-than-expected results or guidance can ripple through broader markets. Australian investors should monitor this as a proxy for global tech sentiment—the ASX tech sector and growth stocks often follow US earnings momentum, particularly when household-name names disappoint.

IBM's Q3 earnings miss has triggered a 5% share price decline, signalling investor disappointment with the company's performance and likely guidance. While IBM is a US-listed stock, it's a significant component of global tech indices and many Australian investment portfolios, so the move matters for diversified investors. Watch for whether this reflects broader weakness in enterprise IT spending or is company-specific—particularly IBM's positioning in high-growth areas like AI and cloud services.

Qiagen has accepted an all-cash takeover bid from EQT at €46.50 per share, valuing the German diagnostics and life sciences company at roughly €12 billion. This represents a significant exit for the business, which provides molecular diagnostics and sample preparation tools widely used in research and clinical labs globally. For Australian investors, this signals consolidation in the biotech/diagnostics space—watch for any Australian-listed healthcare or diagnostics firms that might attract similar acquisition interest, and monitor whether this deal's valuation multiples influence ASX healthcare sector sentiment.

Dow Chemical reported Q3 net sales of $11.3B, up 13% year-over-year with growth across all business segments—a solid earnings beat suggesting broad-based demand recovery. This is a positive signal for cyclical industrials and chemical stocks, though the company's performance is closely tied to global economic momentum and commodity prices. Australian investors with exposure to materials and industrials should watch whether Dow guides higher for full-year earnings and whether management comments on demand sustainability heading into 2024.

Honeywell missed Q3 revenue expectations but responded by raising full-year 2026 guidance, signalling management confidence in forward momentum despite near-term softness. This mixed result reflects broader industrial sector dynamics—near-term headwinds offsetting longer-term growth visibility. For Australian investors, Honeywell's guidance shift matters for ASX-listed industrials and defence-adjacent plays, as it suggests demand recovery trajectory in aerospace and building automation sectors that support global supply chains.

European equity markets are declining as companies report earnings results, with Barclays announcing a significant workforce reduction of 5,000 roles. This suggests the bank is facing profitability pressures and cutting costs in response to a tougher operating environment—a trend that often signals weakness in financial sector demand and consumer credit conditions. For Australian investors, this reflects broader concerns about global banking health and may weigh on ASX financials, particularly if Australian banks face similar earnings headwinds.

The ASX closed lower as weakness in energy, mining, and retail stocks pressured the broader market, with furniture retailer Nick Scali's profit warning serving as a canary in the coal mine for discretionary spending. The pullback reflects ongoing concerns about consumer demand and margin pressure in cyclical sectors, particularly relevant for Australian investors given the ASX's heavy weighting to materials and energy. Watch for further earnings disappointments in the consumer and discretionary space as retailers report results amid sticky inflation and rising rates.

Meta reported strong ad revenue this quarter, but the real driver of investor enthusiasm is the emerging Muse personal assistant—a potential new revenue stream that could eventually eclipse advertising. This matters because Meta's valuation has long depended on ad growth, which faces headwinds from privacy regulation and competition; a successful AI assistant business could reshape the company's growth trajectory. Australian investors should watch how this new business scales and whether it can justify Meta's premium valuation, while also monitoring regulatory responses to AI assistants in key markets.